Internal Med Medical News about Migraine Disorders Trastuzumab

Your Unread Messages

See All

Tracy Hampton, PhD

FDA Update

Anti-CD20 Antibody Granted Accelerated Approval for CLL

Roberta Buell, MBA
OIG Seeks Revisions to the “Incident To” Rule

Dorothy J. Schirf, MD

Technology Advances

Magnetic Nanosensor Prepped for Early Cancer Detection

Sara Hartley

Cancer Science

The Depressing Thing About Cancer

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

5. Rapid correction of low vitamin D status in nursing home residents

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A Throbbing Pain in the Head: Trastuzumab-induced Migraine
Anticancer Research, 11/06/09

Van Rooij F et al. – Trastuzumab, an epidermal growth factor receptor inhibitor, is used in the treatment of both early–stage and metastatic breast cancer. In general it is well tolerated, with a flu–like syndrome occurring frequently a few hours after administration, including symptoms such as fever, sweating, skin rash, nausea and headache. A migraineous headache however has never been described as an adverse event. Here the authors present a patient in whom a strong relationship between trastuzumab infusion and a migraineous headache syndrome was present, without evidence of metastatic disease. Treatment with corticosteroids for the infusion–related complaints resulted in significant pain relief.

<< Previous
Genetic modulation of the pharmacological treatment of pain

Next >>
Mechanisms and Functional Implications of Intestinal Barrier...